Based on the patient's medical report, the most relevant clinical trials are:

1. **NCT04296370: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib±Apatinib Versus Physicians Choice Chemotherapy in the Treatment of HER2-negative Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations**

The patient is eligible for this trial because they have a germline pathogenic BRCA1 mutation, HER2-negative metastatic breast cancer, and have received prior treatments with ado-trastuzumab emtansine and capecitabine/lapatinib.

Expected prognosis outcome: The trial aims to assess the efficacy and safety of Fluzoparib±Apatinib compared to physician's choice chemotherapy in patients with HER2-negative metastatic breast cancer and germline BRCA1/2 mutations. The patient may benefit from this trial if they experience a better response to the experimental treatment.

Possible risks associated: The trial involves the use of a new drug combination, which may have unknown side effects. The patient should be aware of the potential risks and benefits before enrolling in the trial.

Contact Information:
Contact: NCT04296370
Email: [contact information not provided]
Phone: [contact information not provided]

2. **NCT06313983: A Phase Ⅲ Randomized, Open Label, Parallel, Multicenter To Assess Efficacy and Safety Study of Hemay022 in Combination With AI In Postmenopausal HER2+/ER+ Advanced Breast Cancer Patients Treated With Trastuzumab-containing Regimens**

The patient is not eligible for this trial because they are premenopausal, not postmenopausal. However, this trial may be considered if the patient's menopausal status changes.

Expected prognosis outcome: The trial aims to assess the efficacy and safety of Hemay022 in combination with AI in postmenopausal HER2+/ER+ advanced breast cancer patients treated with trastuzumab-containing regimens. The patient may benefit from this trial if they experience a better response to the experimental treatment.

Possible risks associated: The trial involves the use of a new drug combination, which may have unknown side effects. The patient should be aware of the potential risks and benefits before enrolling in the trial.

Contact Information:
Huiping Li - CONTACT
Phone: 13811012595
Email: huipingli2012@hotmail.com

3. **NCT05955833: 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study**

The patient is eligible for this trial because they have HER2+ breast cancer with metastatic disease.

Expected prognosis outcome: The trial aims to assess the use of 89Zr-DFO*-Trastuzumab PET in patients with HER2+ breast cancer. The patient may benefit from this trial if they experience a better response to the experimental diagnostic test.

Possible risks associated: The trial involves the use of a new diagnostic test, which may have unknown side effects. The patient should be aware of the potential risks and benefits before enrolling in the trial.

Contact Information:
Jelijn Knip, MD - CONTACT
Phone: +31 6 21 45 55 45
Email: j.knip1@amsterdamumc.nl
Hylke Sebus, MD - CONTACT
Phone: +31 6 25 71 60 36
Email: h.j.sebus@amsterdamumc.nl